B+
Bull case
25%
Probability
Target price
$590.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
CHE
ChemedBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The Q2 print materially strengthened the operating case: VITAS delivered double-digit revenue growth, stronger admissions and margins, and management raised full-year guidance. The 2026-07-30 Benzinga analyst-ratings page reports that RBC maintained Sector Perform while raising its target from $436 to $548, supportive but not an outright bullish revision.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.4.
What can break
Analyst revision breadth remains limited and no broad post-earnings estimate consensus was confirmed.
Momentum
46
Value
58
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $545.00 · Bull $590.00 · Bear $475.00Analysis 2026-07-31; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-31 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $552.00
Why
Momentum46 · Δ7d -14.1
Value58 · Δ7d -0.1
Sentiment68 · Δ7d +5.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.4.
Contradictions & invalidation
- • Analyst revision breadth remains limited and no broad post-earnings estimate consensus was confirmed.
- • Roto-Rooter adjusted EBITDA and margin may remain pressured.
- • Roto-Rooter remains weak on profitability, VITAS still has $7.0 million of Medicare Cap billing limitation across four provider numbers, and the stock is already above most available target indications.
Catalyst clock
2026-07-28
Q2 earnings and raised full-year guidance
Lead driver: Sentiment · See AI snapshot
Momentum
46
9% active weight
Current posture
7d trendSoftening
Δ7d
-14.1
Δ21d
-37.0
Value
58
28% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-1.9
Sentiment
68
62% active weight
Current posture
7d trendImproving
Δ7d
+5.4
Δ21d
+4.6
Why this grade
Composite grade B. Momentum 46.0 / Value 58.4 / Sentiment 68.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-31. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$545.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$475.00
Analysis reference price unavailable
Analysis 2026-07-31 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$6.86B
Beta
0.44
Shares Out
13.07M
P/E (TTM)
23.2
P/S (TTM)
2.45
P/FCF (TTM)
18.81
Rev YoY
+8.8%
EPS YoY
+43.7%
Gross Margin
+30.4%
Op Margin
+13.5%
Net Debt
$80.24M
Current Ratio
0.91
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data